An interventional study of Home Monitoring provided by Biotronik ICD and CRT-D devices and No Home Monitoring in Ventricular Fibrillation, Tachycardia, Ventricular and Ventricular Flutter, sponsored by Biotronik SE & Co. KG. Terminated at 17 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-07-02.
Sponsored by Biotronik SE & Co. KG · Not applicable, Interventional, and Treatment
BIOTRONIK Home Monitoring (HM) service enables the doctors to safely follow up (FU) their ICD and CRT-D patients in a remote fashion, with fewer in-clinic consultations. This may result in a more efficient FU and cost-savings for the health care payer.
The EuroEco study:
The EuroEco is a prospective, international, randomized study aimed at assessing the economic effects of BIOTRONIK Home Monitoring (HM) technology as compared with traditional follow up (FU) of ICD and CRT-D patients from two perspectives: 1) the cost-effectiveness for the payer of health care, and 2) the economic impact on the physician, hospital and patient. The study outlines a new model for the FU of ICD-and CRT-D patients based on a combination of in-clinic consultations and regular check ups of the patient data received through the HM service.
About 312 patients with an indication for ICD therapy and 104 patients with an indication for de novo CRT-D implantation should be enrolled. All patients will be implanted with BIOTRONIK ICD or CRT-D devices from the Lumax families and randomized (1:1) to the traditional, or to HM-based FU model. Traditional FU will be performed according to the local clinical practice. Patients in the HM study arm will first undergo local clinical FU routine until the first in-clinic visit after patient discharge. Thereafter routine in-clinic FUs are scheduled at 12 and 24 months. Three HM data checks should be carried out during each 12-month interval, to assess the patient/ICD/CRT-D status remotely.
In both (HM and no HM) groups, additional in-hospital FU may be scheduled any time the patients reports symptoms which are presumed to be cardiovascular symptoms. In the HM group, additional in-clinic FU may also be scheduled as a result of specific HM findings.
The following FU-related activities were accounted for: in-clinic consultations, patients contact, discussion with colleague physician, nurse or technician and arranging in clinic consultation. In HM patients, two additional HM-related FU activities were taken into account: 1) checking the website of BIOTRONIK HM Service Center, and 2) checking HM-related emails and faxes (provided by BIOTRONIK HM Service Center)..
Several tools were made available to document the time that physicians, nurses and technicians spend with these FU activities without disrupting their clinical routine much:
A user manual for time measurements was handed out to physicians, nurses and technicians to recommend which tool should be used in which clinical situation. The average time per patient followed according to the traditional FU model and the average time per patient followed by the HM-based FU model will be calculated for each of the three health care professionals considered (physicians, nurses and technicians). The difference in costs between the traditional and the HM-based FU will be assessed for statistical significance.
This trial may provide data warranting a change in the guidelines for the use of ICD and CRT-D devices featuring HM function, in that HM may justify a prolongation of the time interval between statutory routine in-clinic FU visits. Coupled with the fact that the information provided by HM helps physicians to recognize some otherwise unsuspected needs for additional FU visits, this may ultimately result in better and more cost-effective health care for all parts involved (patients, providers and payers).
623 studies on the registry are indexed under Tachycardia; 81 are open to participants now.
This study's enrollment of 409 is above the median of 64 across 379 interventional studies indexed under Tachycardia.
Browse Tachycardia studies →Biotronik SE & Co. KG is the lead sponsor of 83 studies on the registry; 6 are open to participants now.
Counted across the registry records on this site, refreshed daily.
ICD Patient Population - Inclusion Criteria
ICD Patient Population - Exclusion Criteria
CRT-D Patient Population - Inclusion Criteria
CRT-D Patient Population - Exclusion Criteria
Remote monitoring of ICD and CRT-D function and patient status
Device: Home Monitoring provided by Biotronik ICD and CRT-D devices
Home Monitoring option is switched off
Device: No Home Monitoring
Remote monitoring of ICD and CRT-D function and patient status may result in more effective follow-up and increased patient safety
Home Monitoring option is switched off (in the same kind of devices as used in the other study arm).
Euro spent to follow up ICD and CRT-D patients
Time frame: 26 months
Average number of in-hospital follow-up visits per patient
Time frame: 26 months
Time to first in-hospital follow-up visit beyond the first post-implantation visit
Time frame: 12 months
Effective financial impact on hospitals / physicians
Time frame: 26 months
Proportion of in-hospital consultations with relevant findings (i.e. necessitating changes in medical therapy, device programming or re-hospitalisations/ interventions)
Time frame: 26 months
Proportion of patients with HM-triggered interventions that, without remote monitoring, would have first been discovered at a subsequent scheduled follow-up
Time frame: 26 months
Incidence of inappropriate ICD shocks
Time frame: 26 months
Changes in quality-of-life (SF-36) from baseline to the 12- and to 24-month follow-up visits
Time frame: 26 months
Plan to share: No
No publications or documents are linked to this record.
This study is terminated, as verified in Jun 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Biotronik SE & Co. KG